摘要
ADP-receptor antagonistPrasugrel is a thienopyridine of the third generation and needs conversion into an active drug metabolite(R-138727).Preclinical and clinical studies showed a more rapid,potent and consistent inhibition of patelet function for prasugrel compared to clopidogrel.Prasugrel has been shown to be of particular benefit in patients with diabetes,especially those on insulin [30%
ADP-receptor antagonistPrasugrel is a thienopyridine of the third generation and needs conversion into an active drug metabolite（R-138727）.Preclinical and clinical studies showed a more rapid,potent and consistent inhibition of patelet function for prasugrel compared to clopidogrel.Prasugrel has been shown to be of particular benefit in patients with diabetes,
出处
《血栓与止血学》
2011年第3期99-100,共2页
Chinese Journal of Thrombosis and Hemostasis
